secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYTOKINETICS INC (CYTK)
CIK:        0001061983
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0000950170-25-104962
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytokinetics Q2 net loss narrows to $134.4M; aficamten PDUFA set Dec 26, 2025
-----------------------------------------------------------------------------

- Net loss of $134.4M ($1.12/sh) vs $143.3M ($1.31/sh) in Q2 2024; revenue $66.8M from Bayer deal.
- Cash, cash equivalents and investments: $1.0B at June 30, down $52.6M QoQ after $75M loan draw.
- FDA late-cycle meeting for aficamten (obstructive HCM) scheduled Sept 2025; PDUFA Dec 26, 2025.
- MAPLE-HCM primary results to be presented in Hot Line Session at ESC 2025.
- FY 2025 GAAP operating expense guidance maintained at $670M-$710M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061983/000095017025104962/0000950170-25-104962-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061983/000095017025104962/cytk-20250807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-104962

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer